Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

Publication date: Mar 26, 2026

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment and are increasingly used in the adjuvant and neoadjuvant setting for malignancies such as melanoma, which often affect younger adults. With improving survival, concerns about long-term safety, including potential effects on fertility, are growing. We conducted a national, multicenter, prospective observational study of female patients

Concepts Keywords
Adults Adjuvant anti-PD-1
Drugs Adolescent
Immunotherapy Adult
Ovarian Chemotherapy, Adjuvant
Younger Female
Fertility
Follicle Stimulating Hormone
Follicle Stimulating Hormone
Humans
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors
Immune-related adverse events
Melanoma
Melanoma
Ovarian function
Ovary
Prospective Studies
Skin Neoplasms
Young Adult

Semantics

Type Source Name
disease MESH melanoma
pathway KEGG Melanoma
disease MESH cancer
drug DRUGBANK Follitropin
disease MESH Skin Neoplasms

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *